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Ubiquinol supplementation modulates energy
metabolism and bone turnover during high
intensity exercise
Javier Diaz-Castro,a,b Pablo Javier Mira-Rufino,b,c Jorge Moreno-Fernandez,a,b
Ignacio Chirosa,d Javier Luis Chirosa,d Rafael Guisadoe and Julio J. Ochoa *a,b
Bone and energy metabolism are profoundly influenced by exercise. The objective of this study was to
determine for the first time whether a short-term supplementation with ubiquinol could have a modu-
lating effect on bone turnover and energy metabolism associated with strenuous exercise. The partici-
pants (n = 100 healthy and well-trained firemen) were randomly divided into two groups: ubiquinol
group (ubiquinol (200 mg day−1)) and control group (placebo) for two weeks. The protocol consisted
of conducting two identical strenuous exercise tests with a rest period between tests of 24 h. Blood
samples were collected before supplementation (basal value) (T1), after supplementation (T2), after
the first physical exercise test (T3), after 24 h of rest (T4), and after the second physical exercise test
(T5). Parathyroid hormone (PTH), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), sclero-
tin (SOST), alkaline phosphatase (AP), adrenocorticotropin (ACTH), insulin, leptin, adrenaline, nor-
adrenaline and peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) were deter-
mined. Our protocol increased ACTH, SOST, PTH and OC levels, while it decreased OPN. This protocol
also increased adrenaline, noradrenaline and PCG-1α, and decreased insulin. After ubiquinol sup-
plementation, PTH, OC, OPG, alkaline phosphatase, leptin, insulin, noradrenaline and PGC-1α levels
increased in the supplemented group compared to the control group after the exercise protocol.
Strenuous exercise has a clear effect on energy metabolism and bone turnover. These effects are
modulated by ubiquinol supplementation, which especially increases the biomarkers of bone for-
mation during strenuous exercise. In addition, ubiquinol has a beneficial effect on the mobilization of
energy sources, fact that it could represent an ergogenic and physiological advantage for skeletal
muscles.
1. Introduction
Numerous reports have revealed that moderate physical activity
enhances the function of various organs and tissues, and it is
associated with a reduced threat of cardiovascular disease,
cancer and diabetes, and in general, with a lower risk of all
causes of mortality.1 One of the tissues influenced by exercise
is bone.2 Exercise is a promoter of bone turnover and a rec-
ommended practice to prevent osteoporosis and bone metab-
olism problems.2
Physical activity can act on bone remodeling directly and
indirectly through various metabolic pathways.3 For this
reason, it is important to consider that bone metabolism
cannot be studied independently of other physiological pro-
cesses that are also affected by exercise, such as energy metab-
olism.4 Thus, bone regulation is part of a complex system
involving mechanisms of central origin (nervous system), sys-
temic (endocrine) and local.5
Bone remodeling occurs in a constant way, which implies a
high energy demand, and therefore, as we have mentioned
earlier, there exists a strong physiological link between bone
tissue, energy metabolism and sympathetic nervous system.3
This physiological link includes hormones from adipose tissue
(such as leptin)3,6 and from bone tissue (osteocalcin), which
have effects on the metabolism of glucose, fatty acids, insulin
secretion and adiponectin, among others.2,3,6 In fact, bone
tissue apart from being a support tissue, has an important
endocrine role regulating energy metabolism and other meta-
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bolic pathways affecting levels of glucose, levels of appetite,
muscle function, among others.7,8
Another important aspect to consider during the intense
physical activity is the high output of free radicals,9 which is
linked to both bone turnover and energy metabolism.3
Oxidative stress can negatively affect bone turnover by increas-
ing bone resorption through increasing activity and prolifer-
ation of osteoclasts10,11 and it has been observed that dietary
supplements with antioxidant capacity have shown positive
effects on bone homeostatic alterations associated with oxi-
dative stress.12
However, although the benefits of moderate physical
activity are evident, high intense exercise does not have these
benefits on body mass density and may cause negative
effects.13 For this reason, elite athletes and other populations,
who continuously practice high intensity exercises, are a group
that must pay special attention to bone health, because of the
possible long-term appearance of bone pathologies such as
osteopenia or osteoporosis, and also for the short-term micro-
fractures.4 One way to reduce this bone damage would be by
modifying training protocols, but this could lead to a decrease
in physical performance, something not desirable for this
group, although it can be improved through the supplemen-
tation with certain nutrients.4 One of such nutrients that
acquires more interest every day is coenzyme CoQ10 (CoQ10),
which has shown properties related to energy metabolism and
antioxidant activity.14 In addition, supplementation with this
molecule has shown positive effects during strenuous exer-
cises,14 as well as on bone turnover,15,16 although the latter
studies were performed in vitro or using animal models.
The data available in the scientific literature have provided
a direct link between physical performance and blood CoQ10
levels.17 However, most of these studies are focused mainly in
the exercise performance and radical-scavenging activity of
CoQ10 during low intensity exercise.17 Virtually, there are no
studies showing the effect of supplementation with CoQ10
during strenuous physical exercise on the modulation of
energy metabolism and bone turnover, especially when using
the reduced form of CoQ10, the ubiquinol, which has shown
greater bioavailability and efficacy than the oxidized form.18
Taking into account all the abovementioned facts, this study
has been designed to assess for the first time whether oral ubi-
quinol short-term supplementation prior to the performance
of a high intensity exercise has a positive role in bone and
energy metabolism, assessing the effects of this agent during
strenuous exercise.
2. Materials and methods
2.1. Subjects
This study is a randomized, double-blind and placebo-con-
trolled trial. 100 firemen of the Fire Department of the City of
Granada (healthy and well-trained) took part in the study.
Participants completed a medical and health history and
physical activity questionnaire (IPAQ-SF)19 prior to enrolment.
All of them were non-smokers, did not take any nutritional
supplements and did not present febrile/inflammatory clinical
symptoms, chronic diseases, bone pathologies, did not use
immunosuppressive or nephrotoxic drugs, and did not use
energy, protein and/or antioxidant supplements. The firemen
were randomly divided into two groups: ubiquinol group (ubi-
quinol) (n = 50) and placebo group (control) (n = 50). The ubi-
quinol group was supplemented with an oral dose of 200 mg
day−1 of ubiquinol for 2 weeks (in the morning, under fasting
conditions with a glass of water), which was administered in 2
brown liquid-filled hard gelatin capsules of 100 mg each, and
the control group took placebo using the same scheme. The
capsules Kaneka QH ubiquinol (Kaneka Corporation, Osaka,
Japan) contained ubiquinol composed of canola oil, diglycerol
monooleate, beeswax and soy lecithin. The placebo capsules
contained the same composition without ubiquinol and were
also supplied by Kaneka (Kaneka Corporation, Osaka, Japan).
All participants signed the informed consent. The study was
approved by the Commission of Ethics in Human Research of
the University of Granada (ref. 804) and it has been registered
in ClinicalTrials.gov, with the number NCT01940627. To avoid
an important confounder in this type of trials, we collected
four-day diet records, including one day of the weekend to
know the nutritional condition of the participants. The infor-
mation obtained in this survey was evaluated by nutrition soft-
ware (Nutriber, v1.1.1.5.r5, FUNIBER, Spain).
2.2. Intense physical exercise performance program
Characteristics, intensity and muscle aggression of this proto-
col were previously checked by measuring blood myoglobin,
lactate and CK.9 After a 2-week period of ubiquinol or placebo
supplementation, subjects performed the strenuous exercise
protocol. Prior to the starting of each test, subjects performed
a warm-up. The protocol consisted of conducting two identical
strenuous exercise tests, with a rest period of 24 hours between
the tests. Both strenuous exercise tests involved performing a
circuit composed of 10 resistance exercises (1, athletic press; 2,
chest press in Smith machine; 3, seated oar; 4, shoulder press;
5, femoral bicep flexion; 6, chest press in Smith machine; 7,
step with weight; 8, surveyor’s pole chest; 9, push with weight;
10, quadriceps extension), with a minimum workload of
approximately to 60–70% of the dynamic maximum force
(DMF or 1RM).9 In order to establish the minimum magnitude
of the load to be displaced for each subject, one week before
the strenuous exercise protocol, a session of pre-training was
held with the subjects to conform the load individually in
terms of two parameters in each exercise: (a) scale
OMNI-RES20 values of perceived exertion between 6 and 7, and
(b) 10 repetitions.
2.3. Blood sampling
Five blood samples were collected from the participants via
venous catheter into heparinized tubes before and immedi-
ately after the physical test. Five blood samples were taken:
before supplementation (basal value) (T1), after supplemen-
tation (2 weeks) and immediately before the first physical exer-
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cise test (T2), after the first physical exercise test (T3), after
24 h of rest and immediately before the second physical exer-
cise test (T4), and after the second physical exercise test (T5).
Blood was immediately centrifuged at 1750g for 10 min at 4 °C
in a Beckman GS-6R refrigerated centrifuge (Beckman,
Fullerton, CA, USA) to separate plasma from red blood cell
pellets. Plasma samples were immediately frozen and stored at
−80 °C until analysis.
2.4. Bone turnover parameters
Luminex xMAP technology-based Milliplex Map Kits were
used. Human Bone Panel 1A (Millipore, USA, cat. no.
HBNMAG-51K) was used for adrenocorticotropic hormone
(ACTH), parathyroid hormone (PTH), osteocalcin (OC), osteo-
pontin (OPN), osteoprotegerin (OPG), sclerotin (SOST), leptin
and insulin determination. Preparation of samples, reagents
and standards were carried out following the manufacturer’s
instructions. The standard curve pattern was performed by
successive dilutions of the stock concentration for each bio-
marker. A standard curve was obtained with the following con-
centrations: OPG, 30 000 pg ml−1; insulin, 250 000 pg ml−1;
leptin, 200 000 pg ml−1; OC, 600 000 pg ml−1; OPN, 400 000 pg
ml−1; PTH, 20 000 pg ml−1. Equipment conditions were set fol-
lowing the manufacturer’s instructions: events: 50 micro-
sphere; sample size: 50 µl; gate settings: 8000–15 000; reporter
gain: default (low PMT); time out: 60 seconds; bead set: OPG/
17; OC/19; leptin/22; PTH/31; insulin/82.
2.5. Alkaline phosphatase (AP)
AP was measured using a BS-200 Chemistry Analyzer
(Shenzhen, China), using a Pointe Scientific Alkaline
Phosphatase liquid reagent (Pointe Scientific, MI, USA), by
measuring the rate of hydrolysis of various phosphate esters
under specified conditions.
2.6. Peroxisome proliferator activated receptor-γ coactivator-
1α (PGC-1α)
Peroxisome proliferator activated receptor-γ coactivator-1α
(PGC-1α) was measured using a commercial kit (Cloud Clone
Corp., TX, USA). The microtiter plate provided is pre-coated
with an antibody specific to PGC-1α. Standards or samples
were added to the appropriate microtiter plate wells. Next,
avidin conjugated to horseradish peroxidase (HRP) was added
to each microplate well and incubated. The enzyme–substrate
reaction was terminated by the addition of sulphuric acid solu-
tion and the color change was monitored spectrophotometri-
cally (Thermo Spectronic, Rochester, USA) at 450 nm.
2.7. Adrenaline and noradrenaline
Adrenaline and noradrenaline were measured using a DRG
Instruments Cat Combi ELISA (catecholamine combination)
commercial kit (Marburg, Germany). After pipetting the
enzyme solutions, incubating and making the subsequent
washes, stop solutions were added to both plates and adrena-
line and noradrenaline were monitored spectrophotometrically
(Thermo Spectronic, Rochester, USA) at 450 nm, following the
manufacturer’s instructions.
2.8. Statistical evaluation
All data are presented as mean ± SEM. All variables were tested
to see if they followed the criteria of normality and homogen-
eity of variance using the Kolmogorov–Smirnov and Levene
tests, respectively. To compare the general characteristics of
the subjects in both experimental groups, unpaired Student’s
t-test was used. To assess the effect of the supplementation
and the evolution in the time of each variable studied in each
experimental group, a general linear model of variance for
repeated measures with an adjustment by means of
Bonferroni’s test was performed. Bonferroni’s test allowed us
to study the intra- and inter-subject differences (effect of time
in each group and supplementation in each period, respect-
ively). A value of p < 0.05 was considered significant. For data
analysis, we used SPSS version 20.0 (SPSS Statistics for
Windows, 20.0.0., SPSS Inc., Chicago, IL, USA).
3. Results
No differences were observed in the general characteristics of
the subjects (Table 1). Also, we have previously published that
there are no significant differences between the groups neither
for the results obtained in the nutritional questionnaire nor in
the physical activity questionnaire, and both groups have been
categorized as category 3, with the highest measurement
threshold of the total physical activity of the questionnaire.
The percentage of dropouts and the reasons for them were,
also, similar in both groups, without significant differences
being observed, as previously reported.9
Bone turnover biomarkers were influenced by exercise and
ubiquinol. ACTH increased with exercise in T3 and T5 in both
groups (p < 0.05) and no effect of ubiquinol was observed
(Fig. 1A). PTH increased in the ubiquinol group compared to
Table 1 Subjects baseline characteristics
Age (years) Height (cm) Weight (kg) BMI (kg m−2) SBP (mmHg) DBP (mmHg) RHR (beats per min)
Ubiquinol 38.9 ± 1.4 175.4 ± 0.8 76.8 ± 1.5 25.0 ± 0.4 137.0 ± 2.2 81.4 ± 1.5 57.4 ± 1.8
Control 38.2 ± 1.2 174.5 ± 1.2 76.3 ± 2.0 25.0 ± 0.5 134.1 ± 2.1 79.1 ± 1.9 57.1 ± 1.5
Data are expressed as mean ± SEM. Abbreviation: BMI (body mass index); DBP (diastolic blood pressure); RHR (resting heart rate); SBP (systolic
blood pressure).
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the control group in T2, T4 and T5 (p < 0.05). With regard to
the evolution, in the ubiquinol group an increase was observed
in T3 compared to T1 and T2 (p < 0.05) and in T5 compared to
T1, T2, T3 and T4 (p < 0.05). In the control group, an increase
was observed in T3 compared to T2 and T4 and in T5 com-
pared to T1, T2 and T4 (p < 0.05) (Fig. 1B). Ubiquinol adminis-
tration induced an increase in the OPG level, being statistically
significant in T3 and T5 (p < 0.05). There were no differences
due to the evolution of time in OPG levels in the ubiquinol
and control groups (Fig. 1C). OPN decreased with exercise in
T1, T2 and T4 in the control group and only in T5 in the ubi-
quinol group (p < 0.05). No differences were observed by the
supplementation (Fig. 1D). With regard to SOST, an increase
was observed in both groups in T3 with respect to T1, T2 and
T4 (p < 0.05). Ubiquinol showed no effect (Fig. 1E). OC
increased in the ubiquinol group compared to the control
group in T2 and T5 (p < 0.05). With regard to the evolution, in
the ubiquinol group the highest value was observed in T3 com-
Fig. 1 Effect of short-term ubiquinol supplementation on: (A) ACTH, (B) PTH, (C) OPG, (D) OPN, (E) SOST, (F) OC and (G) alkaline phosphatase
during high intensity exercise. Data are expressed as mean ± SEM. Asterisk indicates statistically significant differences between groups (P < 0.05).
Different letters in every group indicate significant differences due to time [control (A, B, C, D and E); ubiquinol (a, b, c, d and e)] (P < 0.05). T1:
before supplementation (basal value); T2: after supplementation (2 weeks) and before the first physical test; T3: after the first physical exercise test;
T4: after 24 h of rest and before the second physical test; T5: after the second physical exercise test.
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pared to T1 (p < 0.05), while in the control group in T3 an
increase was observed compared to T1, T2, T4 and T5 (p <
0.05) (Fig. 1F). AP levels were higher in the ubiquinol group
compared to the control group, being statistically significant
in T2, T3 and T4 (p < 0.05). With regard to the evolution, no
differences were observed (Fig. 1G).
Insulin was higher in the ubiquinol group compared to the
control group in T4 (p < 0.05). With regard to the evolution, in
the ubiquinol group the highest value was observed in T4 com-
pared to T3 and T5 (p < 0.05), while in the control group an
increase was observed in T2 compared to T3 and T5 (p < 0.05)
(Fig. 2A). Leptin was always higher in the ubiquinol group
compared to the control group, being statistically significant
in T2, T3 and T4 (p < 0.05). With regard to the evolution, in
both groups there were no statistically significant differences
in the insulin levels (Fig. 2B).
Adrenaline levels do not show statistically significant differ-
ences between the groups. With regard to the evolution, the
highest value in the ubiquinol group was observed in T3 com-
pared to T1, T2 and T4 (p < 0.05). In the control group, the
maximum value was also observed in T3 compared to the rest
of the time line points (p < 0.05) (Fig. 3A). Noradrenaline
increased in the ubiquinol group compared to the control
group in T3 and T5 (p < 0.05). With regard to the evolution, in
the ubiquinol group the highest level of noradrenaline was
observed in T3 and T5 compared to T1, T2 and T4 (p < 0.05)
(Fig. 3B).
PGC-1α increased in the ubiquinol group compared to the
control group in T3, T4 and T5 (p < 0.05). With regard to the
evolution, in the ubiquinol group the highest value was
observed in T3 and T5 compared to T1 and T2 (p < 0.05), like
the increase observed in the control group in T5 compared to
T1, T2 and T3 (p < 0.05) (Fig. 4).
4. Discussion
According to the American College of Sports Medicine, moder-
ate intensity, weight-bearing endurance activities are rec-
ommended to help preserve or increase bone mass in adults.21
It has been demonstrated that exercise may positively affect
strength, density, cortical geometry and trabecular microarchi-
tecture.22 The effect of physical activity on the process of bone
remodeling can be direct (dependent on the type of physical
activity, duration and especially load) and indirect through
Fig. 2 Effect of short-term ubiquinol supplementation on (A) leptin and
(B) insulin levels during high intensity exercise. Data are expressed as
mean ± SEM. Asterisk indicates statistically significant differences
between groups (P < 0.05). Different letters in every group indicate sig-
nificant differences due to time [control (A, B, C, D and E); ubiquinol (a,
b, c, d and e)] (P < 0.05). T1: before supplementation (basal value); T2:
after supplementation (2 weeks) and before the first physical test; T3:
after the first physical exercise test; T4: after 24 h of rest and before the
second physical test; T5: after the second physical exercise test.
Fig. 3 Effect of short-term ubiquinol supplementation on (A) adrena-
line and (B) noradrenaline levels during high intensity exercise. Data are
expressed as mean ± SEM. Asterisk indicates statistically significant
differences between groups (P < 0.05). Different letters in every group
indicate significant differences due to time [control (A, B, C, D and E);
ubiquinol (a, b, c, d and e)] (P < 0.05). T1: before supplementation (basal
value); T2: after supplementation (2 weeks) and before the first physical
test; T3: after the first physical exercise test; T4: after 24 h of rest and
before the second physical test; T5: after the second physical exercise
test.
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various endocrine metabolic pathways.3 However, continued
situations of high intensity or strenuous exercise, as can
happen with elite athletes, can lead to a negative effect on
bone tissue, so this group must pay special attention to their
bone health, both for possible long-term and short-term
damages.4 In addition, when studying bone metabolism, it
must be considered as part of a complex system that includes
the mechanisms of central origin (SN), endemic (endocrine)
and local.3–5 Before beginning to discuss the results obtained
in this study, we would like to indicate that, previously,10 we
have shown that the exercise protocol performed is of high
intensity (increase in lactate of 290% after the first exercise
test and 350% after the second exercise test) and induces
muscle damage (increased myoglobin after the first and
second exercise tests, 358% and 387% respectively, and
increased CK-MM levels of 158% after the first exercise session
and 196% after the second). These increases were similar to
those observed in other strenuous exercise tests.23 We have,
also, reported that our supplementation with ubiquinol effec-
tively increases plasma CoQ10 up to five times higher levels.9
The exercise protocol showed a clear effect on bone turn-
over, with a higher incidence in the biomarkers of formation,
as has been indicated by other authors.2 Our exercise
increased ACTH, PTH, osteocalcin and decreased OPN (related
to a greater bone formation) and increased SOST (related to
resorption). Also, our exercise protocol increased adrenaline,
noradrenaline and PGC-1α, and decreased insulin, showing
that all these results indicate a positive effect on the mobiliz-
ation of glucose, fatty acids and energy metabolism.
Physical activity and especially strenuous exercise can cause
a decrease in serum total and ionized Ca, which is a trigger for
PTH secretion.24 PTH is one of the main hormones involved in
Ca metabolism,25–27 and it has been assigned for catabolic
and anabolic actions in bone.5 A continuous or chronic
increase in the output of this hormone, as observed in patho-
logical situations, stimulates the processes of bone resorption
(through induction of the receptor activator for nuclear factor
κ B ligand [RANKL] and inhibition of OPG),26,28,29 while inter-
mittent increases, such as those associated with physical exer-
cise, show a clear anabolic effect for bone tissue.28 This posi-
tive effect on bone formation is due to various mechanisms,
stimulates the differentiation and proliferation of osteoblasts,
and stimulates OC levels and decreases SOST.28,29 In addition,
that beneficial effect of PTH has been associated with an
increase in blood flow to bone showing a local vasodilatory
effect.30 This aspect is interesting, given the importance of an
adequate blood supply for a correct bone formation and the
fact of having observed vasodilation and angiogenesis of the
osseous blood vessels during exercise.30 In the current study,
ubiquinol supplementation induced an increase in PTH
(higher than that observed by exercise alone), which presum-
ably could improve its effect on bone. In addition, a previous
study of our research group9 showed a vasodilatory effect of
ubiquinol supplementation by increasing nitric oxide (NO),
which would improve this beneficial effect on bone tissue.
The bone remodeling process requires a balance between
resorption and formation, with OPG/RANK signaling being a
key path in regulating this balance.7 Our exercise protocol
showed no effect on OPG, although in other studies the results
have been contradictory;31 however, an increase was observed
with our ubiquinol supplementation, which could have a ben-
eficial effect on bone formation.7
Another very interesting effect of the ubiquinol supplemen-
tation in the current study was the effect on AP, showing
higher values than the placebo group in T2, T3 and T4. This
enzyme, in the absence of liver damage, is one of the most
used biomarkers of bone metabolism,2 indicating osteoblastic
activity. In relation to exercise, no effect on this biomarker was
observed, although in the literature there is controversy about
the effect of exercise on alkaline phosphatase.2
Together with PTH, OPG and AP, OC has also been reported
to indicate the newly synthesized bone.25 OC is a non-collage-
nous protein of osteoblast origin, highly represented in the
bone extracellular matrix and actively involved in bone for-
mation,32 and its levels have a correlation with the number of
osteoblasts and bone formation, as well as with the proportion
of new bone generation.3 Our results show an increase in OC
associated with our exercise protocol and that this increase is
greater in the ubiquinol group and these hormones reflect the
bone formation rate, fact that it is related with significant
increments in bone mass.33 Therefore, in the light of these
results, we can affirm that ubiquinol supplementation during
exercise could increase bone turnover rate.
However, as we have commented previously, we cannot
study bone turnover independently of the other physiological
processes, being one of the reasons of this fact, which is the
endocrine effect of OC.6,8 It has been described that this
hormone favors adaptation to exercise, featuring a critical role
on energy metabolism, by acting on glucose and fat metab-
olism, stimulation of insulin (bone-pancreas loop),8 prolifer-
Fig. 4 Effect of short-term ubiquinol supplementation on PCG-1α
levels during high intensity exercise. Data are expressed as mean ± SEM.
Asterisk indicates statistically significant differences between groups (P <
0.05). Different letters in every group indicate significant differences due
to time [control (A, B, C, D and E); ubiquinol (a, b, c, d and e)] (P < 0.05).
T1: before supplementation (basal value); T2: after supplementation (2
weeks) and before the first physical test; T3: after the first physical exer-
cise test; T4: after 24 h of rest and before the second physical test; T5:
after the second physical exercise test.
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ation of pancreatic cells and induction of adiponectin,2,3,6 and
also, in muscle capacity and cognitive capacity.8 This clear link
between OC and energy metabolism has led to consider that
the changes in the activity of osteocalcin during physical exer-
cise, mainly respond to an adaptation to a greater energy need
and thereby to the mobilization of substrates such as glucose
and fatty acids.8 It is important to emphasize once again that
the effect on OC associated with our exercise protocol is
increased by ubiquinol supplementation.
Another hormone that has been involved in this physiologi-
cal link between bone turnover and energy metabolism and
increased ubiquinol supplementation is leptin, an adipokine
associated with appetite suppression regulation, energy
homeostasis, immunology, and respiration, among other bio-
logical actions and that regulates energy metabolism by direct
effects on central nervous system and skeletal muscle tissue.28
The relationship between leptin and bone tissue is complex
and controversial. It seems to act through a direct peripheral
pathway with stimulation on bone formation and growth
(differentiation of osteoblasts, inhibition of apoptosis,
increased mineralization and induced expression of OPG) and,
also, through an indirect central pathway via hypothalamus
and sympathetic nervous system that seems to reduce bone
formation and have an effect on resorption.34 Therefore,
although the effects of leptin on energy metabolism are clear,
its influence on bone tissue is doubtful, indicating that it
could be effective only in extreme situations.34
Leptin also has a clear effect on insulin3,6 and enhances the
expression of noradrenaline.34 The reduction of insulin,
associated with sport,35 reduces gluconeogenesis and
increases the bioavailability of glucose and fatty acids, an
effect that is enhanced by the increase in adrenaline and
noradrenaline.36,37 Thus, an increase in noradrenaline associ-
ated with physical exercise shows a clear effect on promoting
glycogenesis and lipolysis,36 but also has an effect on bone
metabolism, increasing PTH and favoring the bone resorption
processes, thanks to the β2-adrenergic receptors existing in
osteoblasts and osteoclasts.34 However, more recent studies
report the existence of α receptors, involved in the formation
processes,38,39 thus showing a complex and controversial
relationship with bone tissue that requires further research.
Finally, we have recorded an increase in PGC-1α associated
with exercise with a higher increase in the ubiquinol group.
PGC-1α is a major factor involved in the regulation of a diverse
array of physiologic processes including adipogenesis, lipid
metabolism, insulin sensitivity and inflammation, interacting
with several nuclear receptors and transcription factors to acti-
vate the transcription of their target genes.40,41 Additionally, in
skeletal muscle, PGC-1α has also been shown to regulate skel-
etal muscle fiber type switch (favoring the exchange of glyco-
lytic fibers to oxidative fibers), glucose transport, lipid utiliz-
ation and mitochondrial biogenesis and fusion.41–43 In
relation to its effect on bone turnover, it has been observed
that its loss in the mesenchymal cells results in an increased
bone loss, due to a decrease in the formation processes and
increased adipogenesis in the bone marrow,41 having a posi-
tive effect on the bone due to its effect on oxidative stress and
inflammation.44 As we have commented, in the current study,
the expression of PGC-1α increased after exercise and
especially with ubiquinol supplementation, which could have
substantial beneficial effects on improving glucose transport,
fatty acid oxidation and the mitochondrial function of skeletal
muscle,41,45 representing an ergogenic effect on the skeletal
muscle. In addition, the increase in noradrenaline recorded
after the exercise tests in the ubiquinol group indicates a
stimulation of glucose uptake and clearance, enhancing the
ability to shift to higher levels of muscular carbohydrate use,37
representing also a metabolic advantage for the myofibres,
because the post-exercise hyperglycemia induced by nor-
adrenaline is necessary for muscle glycogen repletion.46
5. Conclusion
To the best of our knowledge, this is the first study to show
beneficial effects of ubiquinol supplementation on bone and
energy metabolism during strenuous exercise, which could
draw high interest in physical performance and muscle recov-
ery during exercise (especially of high intensity). Ubiquinol
supplementation is able to enhance bone turnover (especially
bone formation) and block some specific detrimental effects,
improving bone metabolism during strenuous exercise. In
addition to the effects on bone, ubiquinol increased OC,
PGC-1α, insulin, leptin and noradrenaline, which can exert
positive effects on skeletal muscle fiber switch, glucose trans-
port and lipid utilization in skeletal muscles, mitochondrial
biogenesis and fusion and muscle glycogen repletion and
recovery, and these could represent an ergogenic and physio-
logical advantage for the skeletal muscles. Therefore, the
knowledge gained from these findings reveals the benefit of
ubiquinol supplementation in athletes performing strenuous
exercise in order to improve bone turnover and energy metab-
olism during high intensity exercise.
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